

Theodoros P Vassilakopoulos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1804541/publications.pdf>

Version: 2024-02-01

256
papers

5,114
citations

126708

33
h-index

118652

62
g-index

256
all docs

256
docs citations

256
times ranked

6789
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2125-2132.	0.8	830
2	Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. <i>Blood</i> , 2019, 134, 1144-1153.	0.6	255
3	Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e511-e522.	2.2	201
4	Antioxidants attenuate the plasma cytokine response to exercise in humans. <i>Journal of Applied Physiology</i> , 2003, 94, 1025-1032.	1.2	149
5	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases. <i>European Respiratory Journal</i> , 2018, 51, 1700745.	3.1	136
6	Senescence and senotherapeutics: a new field in cancer therapy. , 2019, 193, 31-49.		116
7	Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. <i>British Journal of Haematology</i> , 2007, 137, 240-243.	1.2	108
8	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care. <i>Oncologist</i> , 2012, 17, 239-249.	1.9	105
9	BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. <i>Blood</i> , 2002, 100, 3935-3941.	0.6	90
10	Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. <i>Blood</i> , 2016, 128, 2666-2670.	0.6	82
11	CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin's Disease: Associations With Presenting Features and Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2002, 20, 1278-1287.	0.8	79
12	Treatment of Splenic Marginal Zone Lymphoma With Rituximab Monotherapy: Progress Report and Comparison With Splenectomy. <i>Oncologist</i> , 2013, 18, 190-197.	1.9	77
13	Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity?. <i>Blood</i> , 2014, 123, 1199-1206.	0.6	76
14	A Novel Immunological Assay for Hepcidin Quantification in Human Serum. <i>PLoS ONE</i> , 2009, 4, e4581.	1.1	72
15	Contribution of Pain to Inspiratory Muscle Dysfunction after Upper Abdominal Surgery. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 161, 1372-1375.	2.5	68
16	Strenuous Resistive Breathing Induces Plasma Cytokines. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 166, 1572-1578.	2.5	64
17	Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. <i>Blood</i> , 2005, 105, 1875-1880.	0.6	61
18	Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome. <i>Clinical Cancer Research</i> , 2003, 9, 2114-20.	3.2	56

#	ARTICLE	IF	CITATIONS
19	Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. <i>Hematological Oncology</i> , 2013, 31, 96-102.	0.8	55
20	Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. <i>European Journal of Haematology</i> , 2006, 77, 300-303.	1.1	47
21	The splenic form of mantle cell lymphoma. <i>European Journal of Haematology</i> , 2002, 68, 12-21.	1.1	45
22	Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research – a consensus document from six scientific societies. <i>International Journal of COPD</i> , 2017, Volume 12, 2593-2610.	0.9	44
23	Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. <i>Blood</i> , 2018, 132, 666-670.	0.6	44
24	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. <i>Cancers</i> , 2021, 13, 4480.	1.7	44
25	Elevated Serum Levels of IL-10 are Associated with Inferior Progression-Free Survival in Patients with Hodgkin's Disease Treated with Radiotherapy. <i>Leukemia and Lymphoma</i> , 2004, 45, 2085-2092.	0.6	43
26	Interferon Alpha-2B (IFN-a) Is an Effective Agent for the Treatment of Primary Cutaneous T- and B-Cell Lymphoma.. <i>Blood</i> , 2004, 104, 2643-2643.	0.6	43
27	B-chronic lymphocytic leukemia: practical aspects. <i>Hematological Oncology</i> , 2002, 20, 103-146.	0.8	41
28	Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. <i>European Journal of Haematology</i> , 2006, 77, 387-394.	1.1	37
29	Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?. <i>Leukemia and Lymphoma</i> , 2014, 55, 1463-1470.	0.6	37
30	Prognostic factors in Hodgkin lymphoma. <i>Seminars in Hematology</i> , 2016, 53, 155-164.	1.8	37
31	Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. <i>European Journal of Haematology</i> , 2017, 99, 409-414.	1.1	37
32	Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study. <i>Blood</i> , 2016, 128, 1107-1107.	0.6	36
33	Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. <i>Leukemia and Lymphoma</i> , 2011, 52, 387-393.	0.6	35
34	Safety and Efficacy of Low-Dose Bexarotene and PUVA in the Treatment of Patients with Mycosis Fungoides. <i>American Journal of Clinical Dermatology</i> , 2008, 9, 169-173.	3.3	34
35	The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma. <i>Haematologica</i> , 2002, 87, 701-8; discussion 708.	1.7	34
36	Non-gastric extra-nodal marginal zone lymphomasâa single centre experience on 76 patients. <i>Leukemia and Lymphoma</i> , 2008, 49, 2308-2315.	0.6	32

#	ARTICLE	IF	CITATIONS
37	Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies. <i>Cancers</i> , 2019, 11, 1071.	1.7	32
38	Differential Diagnosis of Waldenström's Macroglobulinemia and Other B-Cell Disorders. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 235-240.	2.1	31
39	Serum levels of soluble syndecan-1 in Hodgkin's lymphoma. <i>Anticancer Research</i> , 2005, 25, 4743-6.	0.5	31
40	Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab. <i>Hematological Oncology</i> , 2013, 31, 10-17.	0.8	30
41	The direct and indirect costs of managing chronic obstructive pulmonary disease in Greece. <i>International Journal of COPD</i> , 2017, Volume 12, 1395-1400.	0.9	28
42	Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. <i>Anticancer Research</i> , 2002, 22, 1845-8.	0.5	28
43	Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. <i>European Journal of Haematology</i> , 2004, 72, 252-258.	1.1	27
44	Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. <i>Haematologica</i> , 2008, 93, 451-454.	1.7	27
45	Bench-to-bedside review: weaning failure--should we rest the respiratory muscles with controlled mechanical ventilation?. <i>Critical Care</i> , 2005, 10, 204.	2.5	26
46	The combination of the load/force balance and the frequency/tidal volume can predict weaning outcome. <i>Intensive Care Medicine</i> , 2006, 32, 684-691.	3.9	25
47	Disease-Related Anemia in Chronic Lymphocytic Leukemia Is Not Due to Intrinsic Defects of Erythroid Precursors: A Possible Pathogenetic Role for Tumor Necrosis Factor-Alpha. <i>Acta Haematologica</i> , 2009, 121, 187-195.	0.7	25
48	Advanced and Relapsed/Refractory Hodgkin Lymphoma: What Has Been Achieved During the Last 50 Years. <i>Seminars in Hematology</i> , 2013, 50, 4-14.	1.8	25
49	How to ventilate obstructive and asthmatic patients. <i>Intensive Care Medicine</i> , 2020, 46, 2436-2449.	3.9	25
50	Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. <i>Hematological Oncology</i> , 2021, 39, 336-348.	0.8	25
51	Topoisomerase II α Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2008, 14, 1759-1766.	3.2	24
52	c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma. <i>Human Pathology</i> , 2014, 45, 565-572.	1.1	24
53	Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens. <i>Oncologist</i> , 2016, 21, 343-353.	1.9	24
54	Immunohistochemical expression and prognostic significance of CCND3, MCM2 and MCM7 in Hodgkin lymphoma. <i>Anticancer Research</i> , 2011, 31, 3585-94.	0.5	24

#	ARTICLE	IF	CITATIONS
55	Correction of Disease Related Anaemia of B-Chronic Lymphoproliferative Disorders by Recombinant Human Erythropoietin: Maintenance is Necessary to Sustain Response. <i>Leukemia and Lymphoma</i> , 2000, 40, 141-147.	0.6	23
56	Ventilatory muscle activation and inflammation: cytokines, reactive oxygen species, and nitric oxide. <i>Journal of Applied Physiology</i> , 2007, 102, 1687-1695.	1.2	23
57	Treatment of splenic marginal zone lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 139-148.	0.7	23
58	Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 765-781.	0.4	22
59	Understanding wasted/ineffective efforts in mechanically ventilated COPD patients using the Campbell diagram. <i>Intensive Care Medicine</i> , 2008, 34, 1336-1339.	3.9	22
60	Treatment of advanced-stage Hodgkin lymphoma. <i>Seminars in Hematology</i> , 2016, 53, 171-179.	1.8	22
61	Autoimmune hemolytic anemia and autoimmune thrombocytopenia at diagnosis and during follow-up of Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1481-1487.	0.6	21
62	Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072090291.	1.1	21
63	Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1 (+) acute myeloid leukemia. <i>European Journal of Haematology</i> , 2004, 72, 58-60.	1.1	20
64	A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 375-384.	0.6	20
65	Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> . 2014, 55, 558-564.	0.6	20
66	Nodal marginal zone lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 1240-1250.	0.6	20
67	Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 240-240.	0.6	20
68	Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL). <i>Blood</i> , 2021, 138, 1366-1366.	0.6	20
69	BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome. <i>Clinical Cancer Research</i> , 2002, 8, 488-93.	3.2	20
70	New Insights in the Mobilization of Hematopoietic Stem Cells in Lymphoma and Multiple Myeloma Patients. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	19
71	Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders. <i>Seminars in Oncology</i> , 2003, 30, 201-205.	0.8	18
72	Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab. <i>Leukemia and Lymphoma</i> , 2008, 49, 1817-1820.	0.6	17

#	ARTICLE	IF	CITATIONS
73	Immunohistochemical Analysis of IL-6, IL-8/CXCR2 Axis, and SOCS-3 in Lymph Nodes from Patients with Chronic Lymphocytic Leukemia: Correlation between Microvascular Characteristics and Prognostic Significance. <i>BioMed Research International</i> , 2014, 2014, 1-13.	0.9	17
74	New Insights into Monoclonal B-Cell Lymphocytosis. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	17
75	Clinical Aspects of Malt Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 262-272.	1.2	17
76	Differential regulation of myofibrillar proteins in skeletal muscles of septic mice. <i>Physiological Reports</i> , 2019, 7, e14248.	0.7	17
77	Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease. <i>Haematologica</i> , 2006, 91, 32-9.	1.7	17
78	EBVD Combination Chemotherapy Plus Low Dose Involved Field Radiation is a Highly Effective Treatment Modality for Early Stage Hodgkin's Disease. <i>Leukemia and Lymphoma</i> , 2000, 37, 131-143.	0.6	16
79	Reversible dilated cardiomyopathy associated with amphotericin B treatment. <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 444-447.	1.1	16
80	Correlation of Fc γ 3 RIIA polymorphisms with latent Epstein-Barr virus infection and latent membrane protein 1 expression in patients with low grade B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2013, 54, 2030-2034.	0.6	16
81	Validation of the simplified prognostic score for splenic marginal zone lymphoma of the Splenic Marginal Zone Lymphoma Working Group. <i>Leukemia and Lymphoma</i> , 2014, 55, 2640-2642.	0.6	16
82	The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine. <i>Clinical Cancer Research</i> , 2016, 22, 1958-1968.	3.2	16
83	Downstaging Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin. <i>Haematologica</i> , 2002, 87, 500-6.	1.7	16
84	Inspiratory resistive breathing induces MMP-9 and MMP-12 expression in the lung. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 308, L683-L692.	1.3	15
85	Recent Advances in Aggressive Large B-cell Lymphomas: A Comprehensive Review. <i>Advances in Anatomic Pathology</i> , 2016, 23, 202-243.	2.4	15
86	Direct and Indirect Costs of Asthma Management in Greece: An Expert Panel Approach. <i>Frontiers in Public Health</i> , 2017, 5, 67.	1.3	15
87	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience. <i>Hematological Oncology</i> , 2018, 36, 174-181.	0.8	15
88	Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. <i>Oncologist</i> , 2021, 26, 597-609.	1.9	15
89	The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group. <i>Hematological Oncology</i> , 2018, 36, 693-700.	0.8	14
90	Early-Stage Gastric MALT Lymphoma: Is It a Truly Localized Disease?. <i>Oncologist</i> , 2009, 14, 148-154.	1.9	13

#	ARTICLE	IF	CITATIONS
91	Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment. <i>Leukemia Research</i> , 2013, 37, 889-893.	0.4	13
92	Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece. <i>Clinical Drug Investigation</i> , 2017, 37, 833-844.	1.1	13
93	Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 950-954.	0.6	13
94	Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 2900-2900.	0.6	13
95	The Significance of PET/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical Trials. , 2017, 37, 5727-5736.		13
96	Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 1657-1686.	1.0	12
97	The role of Src & ERK1/2 kinases in inspiratory resistive breathing induced acute lung injury and inflammation. <i>Respiratory Research</i> , 2017, 18, 209.	1.4	12
98	Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective. <i>BMC Cancer</i> , 2020, 20, 1088.	1.1	12
99	Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2021, 193, 488-496.	1.2	12
100	The presence of CD55- and/or CD59-deficient erythrocytic populations in patients with rheumatic diseases reflects an immune-mediated bone-marrow derived phenomenon. <i>Medical Science Monitor</i> , 2014, 20, 123-139.	0.5	12
101	Correlation of Fc Gamma RIIA Polymorphisms with EBV-Positivity and LMP1 Expression in Patients with Low Grade B-Cell Lymphomas. <i>Blood</i> , 2011, 118, 1600-1600.	0.6	12
102	Is loaded breathing an inflammatory stimulus?. <i>Current Opinion in Critical Care</i> , 2005, 11, 1-9.	1.6	11
103	Kikuchi's lymphadenopathy: a relatively rare but important cause of lymphadenopathy in Greece, potentially associated with the antiphospholipid syndrome. <i>Rheumatology International</i> , 2010, 30, 925-932.	1.5	11
104	A PET-topic in primary mediastinal large B-cell lymphoma: positive or negative, and how to handle it in the end. <i>Leukemia and Lymphoma</i> , 2015, 56, 3-5.	0.6	11
105	The differential effects of inspiratory, expiratory, and combined resistive breathing on healthy lung. <i>International Journal of COPD</i> , 2016, Volume 11, 1623-1638.	0.9	11
106	Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 65-72.	0.7	11
107	Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. <i>Journal of Hematology and Oncology</i> , 2021, 14, 111.	6.9	11
108	CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome. <i>Pathology Research and Practice</i> , 2021, 225, 153567.	1.0	11

#	ARTICLE	IF	CITATIONS
109	Mutation analysis of IgVH genes in splenic marginal zone lymphomas: correlation with clinical characteristics and outcome. <i>Anticancer Research</i> , 2009, 29, 1811-6.	0.5	11
110	Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma. <i>Blood</i> , 2006, 107, 1240-1241.	0.6	10
111	Nitric oxide production in the ventilatory muscles in response to acute resistive loading. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2007, 292, L1013-L1022.	1.3	10
112	Incorporating novel agents in the treatment of myelodysplastic syndromes. <i>Leukemia Research</i> , 2010, 34, 6-17.	0.4	10
113	Detection of L265P MYD88 mutation in a series of clonal B-cell lymphocytosis of marginal zone origin (CBLMZ). <i>Hematological Oncology</i> , 2017, 35, 542-547.	0.8	10
114	The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. <i>American Journal of Hematology</i> , 2018, 93, 895-901.	2.0	10
115	Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. <i>Annals of Hematology</i> , 2021, 100, 2279-2292.	0.8	10
116	A Randomized Trial Comparing Intensified CNOP vs. CHOP in Patients with Aggressive Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 635-644.	0.6	9
117	Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1506-1508.	0.6	9
118	Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. <i>Annals of Hematology</i> , 2019, 98, 1383-1392.	0.8	9
119	Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096612.	1.1	9
120	Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab. <i>Cancers</i> , 2022, 14, 1917.	1.7	9
121	Hodgkin's lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after conventional salvage therapy. <i>European Journal of Haematology</i> , 2002, 68, 289-298.	1.1	8
122	Can resistive breathing injure the lung? Implications for COPD exacerbations. <i>International Journal of COPD</i> , 2016, Volume 11, 2377-2384.	0.9	8
123	Prognostic significance of signal transducer and activator of transcription 5 and 5b expression in Epstein-Barr virus-positive patients with chronic lymphocytic leukemia. <i>Cancer Medicine</i> , 2016, 5, 2240-2248.	1.3	8
124	Adult T-Cell Leukemia/Lymphoma (ATLL): Report of Two Fully Documented Hellenic Patients. <i>Leukemia and Lymphoma</i> , 2004, 45, 715-721.	0.6	7
125	Apoptotic and proliferative characteristics of proliferation centers in lymph node sections of patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 571-582.	0.6	7
126	Multifocal Bilateral Breast Cancer and Breast Follicular Lymphoma: A Simple Coincidence?. <i>Journal of Breast Cancer</i> , 2015, 18, 296.	0.8	7

#	ARTICLE	IF	CITATIONS
127	Regulation of breathing pattern by IL-10. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2019, 317, R190-R202.	0.9	7
128	Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3 ⁺ T cells represents a potential antitumor mechanism of azacitidine. Blood Advances, 2021, 5, 129-142.	2.5	7
129	Significance of the detection of paroxysmal nocturnal hemoglobinuria clones in patients with multiple myeloma undergoing autologous stem cell transplantation. Hematology/ Oncology and Stem Cell Therapy, 2015, 8, 150-159.	0.6	6
130	Role of FDG-PET/CT in staging and first-line treatment of Hodgkin and aggressive B-cell lymphomas. Memo - Magazine of European Medical Oncology, 2015, 8, 105-114.	0.3	6
131	Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome. Scientific Reports, 2016, 6, 21252.	1.6	6
132	Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis. Hematological Oncology, 2018, 36, 645-650.	0.8	6
133	<p>Spontaneous Breathing Through Increased Airway Resistance Augments Elastase-Induced Pulmonary Emphysema</p>. International Journal of COPD, 2020, Volume 15, 1679-1688.	0.9	6
134	Whatâ€™s new about pulmonary hyperinflation in mechanically ventilated critical patients. Intensive Care Medicine, 2020, 46, 2381-2384.	3.9	6
135	TAC1 Mutations in Primary Antibody Deficiencies: A Nationwide Study in Greece. Medicina (Lithuania), 2021, 57, 827.	0.8	6
136	Gastric involvement in patients with primary mediastinal large B-cell lymphoma. Anticancer Research, 2014, 34, 6717-23.	0.5	6
137	Defining a training framework for clinicians in respiratory critical care. European Respiratory Journal, 2014, 44, 572-577.	3.1	5
138	No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab. Leukemia and Lymphoma, 2016, 57, 2705-2708.	0.6	5
139	Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?. Leukemia and Lymphoma, 2017, 58, 1743-1746.	0.6	5
140	Prediction of dysnatremias in critically ill patients based on the law of conservation of mass. Comparison of existing formulae. PLoS ONE, 2018, 13, e0207603.	1.1	5
141	Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS).. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019045.	0.5	5
142	Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group. Journal of Geriatric Oncology, 2020, 11, 121-124.	0.5	5
143	Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	5
144	Genotype-Phenotype Relationships in Inheritable Idiopathic Pulmonary Fibrosis: A Greek National Cohort Study. Respiration, 2022, 101, 531-543.	1.2	5

#	ARTICLE	IF	CITATIONS
145	Hepatic and renal plasma cell lesions in a patient with multiple myeloma in hematological remission. <i>Anticancer Research</i> , 2007, 27, 571-4.	0.5	5
146	Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance. <i>Leukemia and Lymphoma</i> , 2022, 63, 799-812.	0.6	5
147	Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: linear pattern and distinct prognostic factors. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	5
148	Uremic pericarditis with tamponade following prolonged continuous hemofiltration. <i>Intensive Care Medicine</i> , 2001, 27, 1958-1959.	3.9	4
149	The Patient-Ventilator Interaction Has a Third Player. <i>Chest</i> , 2009, 136, 957-959.	0.4	4
150	Comment on "Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial". <i>Haematologica</i> , 2015, 100, e480-e481.	1.7	4
151	Functional p53 can modulate the relationship between E2F-1 expression and tumor kinetics in Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 748-754.	0.6	4
152	Thioredoxin-1, chemokine (C-X-C motif) ligand-9 and interferon- β expression in the neoplastic cells and macrophages of Hodgkin lymphoma: clinicopathologic correlations and potential prognostic implications. <i>Leukemia and Lymphoma</i> , 2017, 58, 2227-2239.	0.6	4
153	A Unique Case of Primary Extranodal Marginal Zone Lymphoma of the Anal Canal. <i>Acta Haematologica</i> , 2019, 142, 87-91.	0.7	4
154	Central nervous system involvement in primary bone marrow or splenic marginal zone lymphoma: Report of two cases and review of the literature. <i>Hematological Oncology</i> , 2019, 37, 219-222.	0.8	4
155	Validation of the simplified International Prognostic Score3 in a Hellenic cohort of patients with advanced-stage Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 190, e335-e339.	1.2	4
156	Relapsed or refractory classical Hodgkin lymphoma: which immunotherapy, and when?. <i>Lancet Oncology</i> , The, 2021, 22, 417-419.	5.1	4
157	Excellent Outcome with Rituximab-CHOP (R-CHOP) Combined with Radiotherapy (RT) in Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).. <i>Blood</i> , 2005, 106, 935-935.	0.6	4
158	Rituximab-CHOP (R-CHOP) and Radiotherapy (RT) for Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).. <i>Blood</i> , 2006, 108, 2745-2745.	0.6	4
159	Pembrolizumab-induced Remission After Failure of Axicabtagene Ciloleucel: Case Report and Literature Review. <i>In Vivo</i> , 2021, 35, 3401-3406.	0.6	4
160	Treatment strategies for pediatric nodular lymphocyte predominant Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1450-1451.	0.6	3
161	Evidence for regulation of oxidative stress by latent membrane protein 1 oncoprotein in patients with low-grade leukemic B cell lymphoma with latent Epstein-Barr virus infection. <i>Leukemia and Lymphoma</i> , 2014, 55, 1904-1909.	0.6	3
162	Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization. <i>Journal of Bone and Mineral Metabolism</i> , 2018, 36, 399-409.	1.3	3

#	ARTICLE	IF	CITATIONS
163	Non-Inherited Maternal Antigens Identify Acceptable HLA Mismatches: A New Policy for the Hellenic Cord Blood Bank. <i>Bioengineering</i> , 2018, 5, 77.	1.6	3
164	p38 Inhibition Ameliorates Inspiratory Resistive Breathing-Induced Pulmonary Inflammation. <i>Inflammation</i> , 2018, 41, 1873-1887.	1.7	3
165	Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes. <i>Hematological Oncology</i> , 2020, 38, 541-553.	0.8	3
166	Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database. <i>Leukemia Research</i> , 2021, 100, 106479.	0.4	3
167	Successful salvage of primary progressive Hodgkin lymphoma with the combination of post-transplant brentuximab vedotin and radiotherapy: Combining novelty and tradition. <i>Hematological Oncology</i> , 2021, 39, 258-262.	0.8	3
168	Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?. <i>Blood</i> , 2021, 137, 2272-2272.	0.6	3
169	Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis. <i>Leukemia Research</i> , 2021, 107, 106595.	0.4	3
170	Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients. <i>Blood</i> , 2014, 124, 2113-2113.	0.6	3
171	The Addition of sFLCR Improves ISS Prognostication in Multiple Myeloma (MM).. <i>Blood</i> , 2007, 110, 1490-1490.	0.6	3
172	Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP). <i>Blood</i> , 2021, 138, 1535-1535.	0.6	3
173	Survivin Messenger RNA Levels in Epstein-Barr Virus-Positive Patients With Leukemic Low-Grade B-Cell Lymphomas Expressing the Latent Membrane Protein 1: Evidence of Apoptotic Function?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 56-60.	0.2	2
174	Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials. <i>Anticancer Research</i> , 2019, 39, 2591-2598.	0.5	2
175	Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry-based cohort study. <i>EJHaem</i> , 2020, 1, 255-261.	0.4	2
176	Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes. <i>Blood Cancer Journal</i> , 2021, 11, 30.	2.8	2
177	Paraneoplastic Intrahepatic Cholestasis in Supradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated With Brentuximab Vedotin: A Case Report and Review of the Literature. <i>In Vivo</i> , 2021, 35, 1951-1957.	0.6	2
178	Tumor Protein 53 Gene Mutations Without 17p13 Deletion Have No Significant Clinical Implications in Chronic Lymphocytic Leukemia. Detection of a New Mutation. <i>Anticancer Research</i> , 2017, 37, 2387-2391.	0.5	2
179	Treatment of Splenic Marginal Zone Lymphoma with Rituximab Monotherapy in 59 Patients. <i>Blood</i> , 2011, 118, 2712-2712.	0.6	2
180	Omitting or reducing radiotherapy in childhood or adolescence Hodgkin Lymphoma. <i>Translational Pediatrics</i> , 2013, 2, 126-30.	0.5	2

#	ARTICLE	IF	CITATIONS
181	The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study. <i>Cancers</i> , 2022, 14, 791.	1.7	2
182	Correspondence re: M. Provencio, et al. the topoisomerase IIa expression correlates with survival in patients with advanced Hodgkin's lymphoma. <i>Clin. Cancer Res.</i> , 9: 1406-1411, 2003. <i>Clinical Cancer Research</i> , 2003, 9, 5430-1; author reply 5431.	3.2	2
183	Rituximab in the treatment of EBV-positive low grade B-cell lymphoma. <i>Anticancer Research</i> , 2013, 33, 5693-8.	0.5	2
184	Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma. <i>Jbuon</i> , 2019, 24, 2483-2489.	0.3	2
185	TRPV4 Inhibition Exerts Protective Effects Against Resistive Breathing Induced Lung Injury. <i>International Journal of COPD</i> , 2022, Volume 17, 343-353.	0.9	2
186	Very Early Onset of Therapy-Related Acute Myeloid Leukemia with 11q23 Rearrangement Presenting with Unusual PET Findings after R-DA-EPOCH for Primary Mediastinal Large B-Cell Lymphoma. <i>Medicina (Lithuania)</i> , 2022, 58, 48.	0.8	2
187	Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma. <i>In Vivo</i> , 2022, 36, 1302-1315.	0.6	2
188	Three-Dimensional Imaging of a Ductus Arteriosus Aneurysm in an Adult. <i>Annals of Thoracic Surgery</i> , 2011, 91, 931.	0.7	1
189	Pure red cell aplasia complicating the course of long-standing mantle cell lymphoma. <i>International Journal of Hematology</i> , 2014, 99, 777-781.	0.7	1
190	Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) with concurrent high grade component at diagnosis: clinico-pathologic features and treatment strategy. <i>Leukemia and Lymphoma</i> , 2015, 56, 3230-3232.	0.6	1
191	Current and emerging treatment approaches for splenic marginal zone lymphoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 897-905.	0.5	1
192	HD2000 Update in Hodgkin Lymphoma—ABVD or BEACOPP?. <i>Journal of Clinical Oncology</i> , 2016, 34, 3584-3585.	0.8	1
193	Hodgkin lymphoma: Introduction. <i>Seminars in Hematology</i> , 2016, 53, 137-138.	1.8	1
194	Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy/autologous hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2018, 100, 131-139.	1.1	1
195	Curative surgery in highly selected patients with heavily pretreated, relapsed/refractory classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 722-726.	0.6	1
196	Pancytopenia, eosinophilia and coagulation disorders in a patient with acute lymphoblastic leukemia in prolonged remission. <i>American Journal of Hematology</i> , 2021, 96, 632-637.	2.0	1
197	Progressive Multifocal Leukoencephalopathy Following Treatment With Obinutuzumab in a Patient With Non-Hodgkin Follicular Lymphoma: A Case Report. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e601-e605.	0.2	1
198	Clinical Implications of the Role of 18FDG-PET/CT in Malignant Lymphomas. , 2014, , 249-265.		1

#	ARTICLE	IF	CITATIONS
199	Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study. <i>Blood</i> , 2019, 134, 5333-5333.	0.6	1
200	First-Line Chemotherapy Leads to High Bone Turnover and Reduced Bone Mass in Patients with Non-Hodgkin's Lymphoma (NHL).. <i>Blood</i> , 2009, 114, 1951-1951.	0.6	1
201	Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia (cll) Prognosis. <i>Blood</i> , 2012, 120, 4568-4568.	0.6	1
202	Increased Serum Transforming Growth Factor-beta1 (Tgf-beta1) Is Related to a Better Outcome in MM, WM and CLL Patients. <i>Blood</i> , 2012, 120, 4976-4976.	0.6	1
203	Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment. <i>Blood</i> , 2014, 124, 4769-4769.	0.6	1
204	Treatment of Hodgkin Lymphoma – New and Developing Therapies and Their Potential Role in Standard of Care. <i>European Oncology and Haematology</i> , 2019, 15, 53.	0.0	1
205	Increased Immunohistochemical CD138 Expression in Waldenström's Macroglobulinemia (WM) in Comparison with Splenic Marginal Zone Lymphoma (SMZL).. <i>Blood</i> , 2009, 114, 5008-5008.	0.6	1
206	Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece. <i>Blood</i> , 2019, 134, 5340-5340.	0.6	1
207	Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	1
208	The immune response to resistive breathing: Implications for respiratory failure. <i>Clinical Intensive Care: International Journal of Critical & Coronary Care Medicine</i> , 2004, 15, 131-144.	0.1	0
209	PET/CT in Hodgkin Lymphoma. , 2016, , 51-107.		0
210	Aggressive B-Cell Lymphomas. , 2016, , 111-171.		0
211	The Role of 18FDG-PET/CT in Malignant Lymphomas: Clinical Implications. , 2018, , 619-647.		0
212	Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group. <i>Leukemia Research</i> , 2018, 71, 55-59.	0.4	0
213	Serum Soluble Syndecan-1 Levels Correlate with Erythropoietin and Inversely with Hemoglobin Levels in Untreated Anaemic Myeloma Patients: Possible Role of Syndecan-1 in the Mechanisms of Chronic Anaemia.. <i>Blood</i> , 2004, 104, 4882-4882.	0.6	0
214	Lymphoma of the Oral Cavity. A Rare Entity with Favorable Prognosis. Ten-Year Experience of a Single Hematology Unit.. <i>Blood</i> , 2004, 104, 4595-4595.	0.6	0
215	B-Chronic Lymphocytic Leukemia (B-CLL), Small Lymphocytic Lymphoma (SLL) and Waldenström's Macroglobulinemia (MW): A Comparative Fish Analysis.. <i>Blood</i> , 2004, 104, 4801-4801.	0.6	0
216	Serum Levels of OPG and MIP-1 α in Untreated Multiple Myeloma Patients. Correlations with Staging, Survival and Bone Disease.. <i>Blood</i> , 2005, 106, 5074-5074.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Rituximab Monotherapy Is an Effective Treatment for Splenic Marginal Zone B-Cell Lymphomas (SMZL).. Blood, 2005, 106, 4800-4800.	0.6	0
218	Retrospective Analysis of 41 Consecutive Patients with Non Gastrointestinal (GI) Extranodal Marginal Zone B-Cell Lymphoma (EMZL): Correlation of Clinical Characteristics and Outcome with Disease Localization.. Blood, 2005, 106, 4785-4785.	0.6	0
219	Molecular Analysis of the VH Gene Usage in a Familial Case of Waldenstrom's Macroglobulinemia.. Blood, 2005, 106, 1005-1005.	0.6	0
220	Topoisomerase III \pm (TopoIII \pm) Expression in Hodgkin's Lymphoma (HL): Correlations with Conventional and Biological Markers and Prognostic Significance under Treatment with ABVD or Equivalent Regimens with or without Radiotherapy (RT).. Blood, 2005, 106, 967-967.	0.6	0
221	Bortezomib in Patients with Relapsed-Refractory Multiple Myeloma (MM). Clinical Observations.. Blood, 2005, 106, 5193-5193.	0.6	0
222	Serum Soluble Syndecan-1 Levels at Diagnosis Constitute an Independent Prognostic Factor of Survival in Myeloma That May Further Differentiate Patients within the ISS Stages.. Blood, 2005, 106, 3404-3404.	0.6	0
223	Z-Guggulsterone Downregulates Survivin and Induces Cell Death in Large B Cell Lymphoma Cells In Vitro.. Blood, 2006, 108, 4752-4752.	0.6	0
224	Serum Free Light Chain Ratio (FLCR) at Diagnosis Constitute a Powerful Prognostic Factor of Survival in Multiple Myeloma (MM).. Blood, 2006, 108, 3522-3522.	0.6	0
225	Efficacy of Rituximab in Hairy Cell Leukemia.. Blood, 2006, 108, 4719-4719.	0.6	0
226	B-Chronic Lymphoproliferative Disorders (BCLD) Presenting with Splenomegaly: Differential Diagnosis and Outcome.. Blood, 2006, 108, 4655-4655.	0.6	0
227	Evaluation of Microsatellite Instability in Gastric MALT Lymphomas.. Blood, 2006, 108, 4625-4625.	0.6	0
228	Long Term Follow up of Hairy Cell Leukemia (HCL) Patients (PTS) Treated with Interferon-Alpha (IFN- α). The Importance of Maintenance.. Blood, 2006, 108, 4718-4718.	0.6	0
229	CD4(+)/CD56(+) Hematodermic (plasmacytoid dendritic cell) Tumor: a Highly Proliferating Neoplasm with Aberrant Expression of Immunohistochemical Markers and Poor Outcome.. Blood, 2009, 114, 2930-2930.	0.6	0
230	Regulation of Apoptosis and Oxidative Stress by LMP1 Oncoprotein of Epstein-Barr Virus in Patients with Low Grade B-Cell Leukemic Lymphomas. Blood, 2011, 118, 5212-5212.	0.6	0
231	Chronic Lymphocytic Leukemia: Proliferative and Apoptotic Profile on Lymph Node, Studied by Immunohistochemistry Including the Proliferation Centers. Blood, 2011, 118, 2538-2538.	0.6	0
232	Determination of the Percentage of CML Patients that Achieve Continuous Complete Molecular Response Under Treatment with TKIs and Are Eligible for Participation in a TKI Discontinuation Study. Blood, 2011, 118, 4446-4446.	0.6	0
233	Impact of Novel M-Component Based Biomarkers On to Progression Free Survival After Treatment in Intact Immunoglobulin Multiple Myeloma.. Blood, 2012, 120, 2927-2927.	0.6	0
234	A Shorter Time to First Treatment and Worst Overall survival Is Observed in CLL Patients with Reduced Serum IgM As Evaluated with Novel Serum Immunoassays. Blood, 2012, 120, 4585-4585.	0.6	0

#	ARTICLE	IF	CITATIONS
235	The Levels of a G-CSF-Inducible pSTAT3+pSTAT5+ Subpopulation of MDS Progenitors with Leukemic Stem Cell Phenotype Predict the Response to Azacytidine. <i>Blood</i> , 2012, 120, 3795-3795.	0.6	0
236	A Comprehensive Immunohistochemical Approach of AKT/mTOR Pathway and p-STAT3 in Mycosis Fungoides. <i>Blood</i> , 2012, 120, 2663-2663.	0.6	0
237	Lower Levels of Survivin in Patients with Leukemic Low Grade B-Cell Lymphomas Expressing LMP1 Oncoprotein of Epstein-Barr Virus. <i>Blood</i> , 2012, 120, 1560-1560.	0.6	0
238	Expression Of CD25 Antigen On CD34+ Cells Is An Independent Predictor Of Survival In Late Stage MDS Patients Treated With Azacitidine. <i>Blood</i> , 2013, 122, 1508-1508.	0.6	0
239	Distinct Profile and Epigenetic Modulation Of STAT Signaling In FOXP3+ T Regulatory Cells Among The Various MDS Subtypes. <i>Blood</i> , 2013, 122, 1509-1509.	0.6	0
240	Evaluation Of Immunoglobulin Variations (Clonal Changes) In Symptomatic Multiple Myeloma (MM) Patients' Course. <i>Blood</i> , 2013, 122, 3173-3173.	0.6	0
241	The Presence Of Spine Bone Plasmacytomas At The Time Of Multiple Myeloma (MM) Diagnosis Confers Poor Prognosis. <i>Blood</i> , 2013, 122, 5366-5366.	0.6	0
242	Presence Of CD55- and/Or CD59-Deficient Erythrocytes In Patients With Rheumatic Diseases: An Immune-Mediated Phenomenon?. <i>Blood</i> , 2013, 122, 3429-3429.	0.6	0
243	Aberrant Immunoglobulin Variations as Indicators of Eventual Clonal Changes in Symptomatic Multiple Myeloma Patients' Course. <i>Current Cancer Therapy Reviews</i> , 2014, 10, 90-96.	0.2	0
244	Composite Lymphomas: A Challenging Entity. <i>Current Cancer Therapy Reviews</i> , 2014, 10, 80-89.	0.2	0
245	CD4+ T Cells in High-Risk MDS Patients Bear an Aberrant STAT Signaling Biosignature. <i>Blood</i> , 2014, 124, 1906-1906.	0.6	0
246	Validation of the Revised International Prognostic Scoring System in 2582 Patients with Myelodysplastic Syndrome: A Multicenter Study By the Hellenic MDS Study Group. <i>Blood</i> , 2016, 128, 2004-2004.	0.6	0
247	17p11.2 Deletions: A Novel Marker of Clinical Aggressiveness in Primary Mediastinal B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 609-609.	0.6	0
248	Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry. <i>Blood</i> , 2018, 132, 5463-5463.	0.6	0
249	The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 5427-5427.	0.6	0
250	Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group. <i>Blood</i> , 2019, 134, 5423-5423.	0.6	0
251	Prognostic Significance of Bone Marrow Cellularity in the Outcome of Patients with Myelodysplastic Syndromes Treated with Azacytidine: A Retrospective Analysis from the Hellenic MDS Study Group. <i>Blood</i> , 2019, 134, 5417-5417.	0.6	0
252	Modulation of the IL-6/STAT3 Signaling Axis in CD4+ T Cells As a Potential Immune Mechanism of Action of Azacytidine in High-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 2988-2988.	0.6	0

#	ARTICLE	IF	CITATIONS
253	Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study. <i>Blood</i> , 2019, 134, 4124-4124.	0.6	0
254	Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients. <i>Blood</i> , 2021, 138, 3752-3752.	0.6	0
255	The immune response to resistive breathing: Implications for respiratory failure. <i>Clinical Intensive Care: International Journal of Critical & Coronary Care Medicine</i> , 2004, 15, 131-144.	0.1	0
256	Symptomatic ovarian involvement as the initial presentation of primary mediastinal large b-cell lymphoma. <i>Gynecologic Oncology Reports</i> , 2022, 41, 100988.	0.3	0